Coeptis Therapeutics, Inc. (COEP)
$
9.5
+0.44 (4.63%)
Key metrics
Financial statements
Free cash flow per share
-2.3146
Market cap
32.3 Million
Price to sales ratio
16.7636
Debt to equity
0.2839
Current ratio
0.8229
Income quality
0.6296
Average inventory
0
ROE
-1.8281
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Coeptis Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of both generic and branded pharmaceutical products, alongside innovative cell therapy platforms aimed at treating cancer. The company incurred an income tax expense of -$1,063,810.00 indicating its tax obligations and reflecting its financial commitments. Its operating expenses amount to $10,054,488.00 encompassing various operational costs incurred during the business cycle. Overall, the total costs and expenses for the company are -$10,054,488.00 which illustrate its comprehensive spending and investment in research and development. The earnings per share (EPS) is reported at -$5.10 highlighting the company’s profitability on a per-share basis, while the cost of revenue for the company stands at $1,038,632.00 showcasing its production and operational expenditures. Coeptis Therapeutics is recognized for significant contributions through its product portfolio, including CD38-GEAR-NK for treating CD38-related cancers and the CD38-Diagnostic screening tool that helps identify suitable candidates for specific monoclonal antibody therapies. In the financial landscape, the company's stock is affordable at $9.50 making it particularly appealing for budget-conscious investors. The stock has an average trading volume of 59,014.00 indicating moderate liquidity, which can facilitate trading activities. With a market capitalization of $33,381,480.00 the company is classified as a small-cap player, positioning itself distinctively within the biopharmaceutical sector. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and innovation. Furthermore, Coeptis Therapeutics belongs to the Healthcare sector, where it continues to drive innovation and growth, making it an intriguing addition for investors looking to engage with forward-thinking biopharmaceutical initiatives.
Is Coeptis Therapeutics, Inc. (COEP) a good investment?
Investing in Coeptis Therapeutics, Inc. (COEP) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Coeptis Therapeutics, Inc. (COEP)'s stock forecast?
Analysts predict Coeptis Therapeutics, Inc. stock to fluctuate between $2.31 (low) and $13.70 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Coeptis Therapeutics, Inc.'s market capitalization?
As of 2025-05-29, Coeptis Therapeutics, Inc.'s market cap is $33,381,480, based on 3,513,840 outstanding shares.
How does Coeptis Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Coeptis Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Coeptis Therapeutics, Inc. (COEP) stock?
To buy Coeptis Therapeutics, Inc. (COEP) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for COEP. Place an order (Market, Limit, etc.).
What is the best time to invest in Coeptis Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Coeptis Therapeutics, Inc. stock ever split?
Coeptis Therapeutics, Inc.'s last stock split was 1:20 on 2024-12-31.
How did Coeptis Therapeutics, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$5.10 | Growth: 514.46%.
Where can I find Coeptis Therapeutics, Inc.'s investor relations reports?
Visit https://coeptispharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Coeptis Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Coeptis Therapeutics, Inc. stock?
All-time high: $280 (2022-01-11) | All-time low: $2.31 (2024-12-31).
What are the key trends affecting Coeptis Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
prnewswire.com
NEW YORK , April 28, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP ), relating to the proposed merger with Z Squared Inc. Under the terms of the agreement, holders of outstanding Z Squared shares will receive equity in Coeptis in exchange for 9,000 U.S. based dogecoin mining machines.
businesswire.com
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) and Z Squared Inc. is fair to Coeptis shareholders. Halper Sadeh encourages Coeptis shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Coeptis and its board vio.
globenewswire.com
Aim to create the largest publicly-traded, Dogecoin-focused mining company in the world Coeptis to spin out biopharmaceutical operations Aim to create the largest publicly-traded, Dogecoin-focused mining company in the world Coeptis to spin out biopharmaceutical operations
globenewswire.com
• COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for broad range of cancers and other therapeutic modalities.
globenewswire.com
This partnership gives COEPTIS access to AI-driven campaign management, predictive analytics, and automated outreach capabilities with MarketLeverage's 5,500 advertisers and 55,000 publishers, creating one of the most expansive and effective affiliate networks in the industry This partnership gives COEPTIS access to AI-driven campaign management, predictive analytics, and automated outreach capabilities with MarketLeverage's 5,500 advertisers and 55,000 publishers, creating one of the most expansive and effective affiliate networks in the industry
globenewswire.com
WEXFORD, Pa., Feb. 13, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a pioneering technology company dedicated to advancing cutting-edge technologies and artificial intelligence at the forefront of innovative biotechnology therapeutic solutions, today announced the launch of COEP Venture Group, a newly established investment arm dedicated to funding and accelerating technology startups specializing in Artificial Intelligence (AI), Robotic Process Automation (RPA), and AI Agents.
See all news
